UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdict ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Anastasios Konidaris - EVP & CFO Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Joseph Todisco - EVP & Chief Commercial Officer, Specialty Conference Call Participants Gregory Gilbert - Truist Securities Daniel Busby - RBC Capital Markets Ami Fadia - SVB Leerink David Amsellem - Piper Sandler & Co. Operator Good morning, and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.01 per share AMRX New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Delaware 32-0546926 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Amneal Pharma ...

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Tasos Konidaris - SVP and CFO Chirag Patel - Co CEO and President Chintu Patel - Co CEO Conference Call Participants Greg Gilbert - SunTrust Randall Stanicky - RBC Balaji Prasad - Barclays Ami Fadia - SVB Leerink Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (S ...